AMT-021: Interim Phase I data

Interim data from an open-label, dose-ranging, Spanish Phase I trial in 8 patients with severe acute intermittent porphyria showed that

Read the full 209 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE